NY-INTANDEM-CAPITAL
11.6.2024 13:01:30 CEST | Business Wire | Press release
InTandem Capital Partners, LLC (“InTandem” or “the Firm”), a middle-market private equity firm focused exclusively on healthcare services, announced today the final closing of InTandem Capital Partners Fund III, LP (“Fund III” or “the Fund”), with $715 million in total capital commitments. Fund III closed above its original target of $650 million.
Consistent with its predecessor funds, Fund III will continue the Firm’s well-established strategy of making control investments in North American payor, provider, and pharmaceutical services businesses using an operationally intensive, hands-on value creation model. InTandem partners closely with founders, entrepreneurs and management teams to accelerate transformational growth.
Fund III secured commitments from a globally diversified group of existing and new investors, including leading endowments, foundations, family offices, healthcare and pension systems, and financial institutions. The Fund is already actively investing, having recently completed its third platform deal in Adams Clinical, a multi-site clinical research management organization focused on late-stage outpatient central nervous system trials.
“We are delighted and grateful for the success of the fundraising for Fund III,” said Elliot Cooperstone, Managing Partner of InTandem. “We view the strong support as a testament to the depth and experience of our team and firmwide reputation built over two decades of partnering with healthcare services entrepreneurs. My colleagues and I are committed to working with great determination to deliver compelling returns and reward the trust of our limited partners.”
“Our long-standing focus on the Healthcare Quintuple Aim – the simultaneous pursuit of enhanced patient experience, elevated provider experience, improved clinical outcomes, greater healthcare equity, and lower cost of care delivery – continues to resonate with institutional investors,” added Brad Coppens, Senior Partner of InTandem. “We believe that investment success is intrinsically linked to alignment with and promotion of the Healthcare Quintuple Aim.”
“We thank our longtime investors for their continued partnership and welcome our new investors joining us in Fund III,” said Lauren Mangino, Principal and Head of Investor Relations and Capital Formation at InTandem. “We appreciate the confidence our limited partners have placed in us. It is a powerful endorsement of InTandem’s investment strategy.”
Kirkland and Ellis LLP served as legal counsel for Fund III and Raymond James acted as placement agent.
About InTandem Capital Partners
InTandem Capital Partners is a private equity firm that invests in and helps accelerate the growth of select healthcare services companies. InTandem is focused on investing in businesses that align with the Healthcare Quintuple Aim – the simultaneous pursuit of enhanced patient experience, elevated provider experience, improved clinical outcomes, greater healthcare equity, and lower cost of care delivery. The Firm is comprised of former business executives and experienced investors, and is qualified to provide strategic, acquisition and operating expertise to help companies increase their value and their contribution to an improved healthcare system. InTandem provides support to the management of its portfolio companies and leverages its network of industry executives to augment its capabilities. For further information, visit: www.intandemcapital.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240611630040/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datavault AI and Biochar Now Combine Insured Carbon Removal Credits with Patented Tokenization Technology9.11.2026 12:45:00 CET | Press release
Datavault AI Inc. (“Datavault” or the “Company”) (Nasdaq: DVLT), today announced a global strategic collaboration with Biochar Now to expand the distribution of verified, insured carbon removal credits through Datavault’s patented tokenization technology and global marketing and distribution capabilities. The partnership is designed to connect Biochar Now’s carbon removal credits with a broader network of buyers while strengthening transparency, traceability and accountability in the carbon markets. Under the agreement, Datavault AI will provide access to its carbon credit tokenization technology, including U.S. Patent No. 12,443,977 and related pending applications. It will also support worldwide demand generation, buyer development, marketing and distribution of eligible Biochar Now carbon credits, while also pursuing listings with existing and future partner exchange platforms. Biochar Now will pay Datavault AI for its technology and services; specific financial terms were not discl
NIQ to Present at 2026 J.P. Morgan Ultimate Services Investor Conference9.11.2026 12:45:00 CET | Press release
NielsenIQ (NYSE: NIQ) (the “Company”, or “NIQ”), a leading global consumer intelligence company, today announced that Jim Peck, Chairman and CEO, and Mike Burwell, CFO will participate in a fireside chat at the J.P. Morgan Ultimate Services Investor Conference on Tuesday, November 17, 2026 at 2:40 pm ET. A live webcast will be available on the NIQ investor relations website at https://investors.nielseniq.com. A replay will also be available on the Company's website following the conclusion of the presentation. About NielsenIQ NielsenIQ (NYSE: NIQ) is a leading consumer intelligence company, delivering the most complete understanding of consumer buying behavior. Combining an unmatched global data footprint, granular consumer and retail measurement, and decades of AI modeling expertise, NIQ helps companies turn complex data into confident action. With operations in more than 90 countries covering approximately 82% of the world’s population and more than $7.4 trillion in consumer spend, N
Compass Pathways Completes COMP360 Psilocybin New Drug Application to U.S. FDA for Treatment-Resistant Depression9.11.2026 12:30:00 CET | Press release
Robust NDA submission supported by data from two highly statistically significant Phase 3 trials and a Phase 2b study that each met its primary endpoint and involved a total of more than 1,000 participants living with highly chronic TRD Deep commercial capabilities in place to enable successful launch execution and broad patient access with launch readiness on track for expected launch in H12027, subject to FDA approval Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today announced the Company completed its submission of a New Drug Application (NDA) to the U.S. FDA for COMP360 psilocybin, its investigational synthetic, proprietary formulation of psilocybin, for treatment-resistant depression (TRD). "People living with treatment-resistant depression have gone too long experiencing disproportionate suffering, despite years of trying available treatment options without meaningful relief. The
Semiconductor Companies Get Tough on AI Investment, but Measuring Returns Remains a Challenge9.11.2026 12:03:00 CET | Press release
HTEC research finds semiconductor companies are ahead in scaling AI, yet fragmented measurement is making it harder to connect engineering gains to business outcomes HTEC, the global AI technology and engineering leader, today released its research on the semiconductor sector, which reveals that the sector is relatively advanced in adopting AI but faces a more difficult challenge: proving that technical improvements translate into measurable business value. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261109039341/en/ HTEC, the global AI technology and engineering leader, today released its research on the semiconductor sector, which reveals that the sector is relatively advanced in adopting AI but faces a more difficult challenge: proving that technical improvements translate into measurable business value. Nearly half (48%) of semiconductor respondents describe their organizations as scaling AI or already AI-native, comp
GoFundMe Surpasses $50 Billion Raised, Celebrating the People Powering a Global Movement of Help9.11.2026 12:00:00 CET | Press release
The inaugural Kind 50 list celebrates the people behind the milestone – and how help brings people closer together GoFundMe today announced that its global community has surpassed $50 billion raised to help individuals and nonprofits around the world. More than 200 million people have donated through GoFundMe, and nearly 40% have given more than once, reflecting the extraordinary scale of people showing up for one another – and continuing to come back to help. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261109255455/en/ Celebrating $50B raised on GoFundMe with The Kind 50. From showing up for a friend in need to mobilizing entire communities, The Kind 50 celebrates people and organizations whose acts of kindness – on and off GoFundMe – made an impact over the past year and inspired others to help. To mark the milestone, GoFundMe is introducing The Kind 50, a celebration of the internet’s kindest people. The inaugural list
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom